The relevant information included in this section is exactly as published on the website of the National Securities Market Commission (CNMV)
Filter results
| Date | Title | Content | |
|---|---|---|---|
| 29/04/2021 | On business and financial situation | The Company informs about the increase of its fill-finish capacity for the manufacture of Moderna’s COVID-19 vaccine outside the United States. | |
| 12/04/2021 | On business and financial situation | The Company releases the press release related to its participation in the manufacture of the active substance of Moderna’s COVID-19 vaccine. | |
| 6/04/2021 | Liquidity contracts and specialists | Liquidity contract: transactions conducted in the first quarter of 2021 | |
| 2/03/2021 | On business and financial situation | The Company releases an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States | |
| 2/03/2021 | On business and financial situation | The Company releases a presentation related to an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States | |
| 24/02/2021 | Annual Corporate Governance Report | ROVI releases the 2020 Annual Corporate Governance Report | |
| 24/02/2021 | Annual Report regarding remuneration of the members of the Board of Directors | ROVI releases the 2020 annual report regarding remuneration of the members of the Board of Directors | |
| 24/02/2021 | On business and financial situation | The company releases the press release related to 2020 financial results | |
| 24/02/2021 | On business and financial situation | ROVI releases the 2020 Results presentation | |
| 24/02/2021 | About corporate governance | The Company informs about the agreements adopted by the Board of Directors |